Información:
Error:
ID
14599
Descripción
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00494091
Link
https://clinicaltrials.gov/show/NCT00494091
Palabras clave
Versiones (1)
- 23/4/16 23/4/16 -
Subido en
23 de abril de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Advanced Renal Cell Carcinoma NCT00494091
Eligibility Advanced Renal Cell Carcinoma NCT00494091
- StudyEvent: Eligibility
Similar models
Eligibility Advanced Renal Cell Carcinoma NCT00494091
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Renal Cell Carcinoma
Item
subjects with histologically confirmed, advanced (stage iv or recurrent disease) rcc. the american joint committee on cancer (ajcc) staging and classification criteria will be used.
boolean
C0007134 (UMLS CUI [1])
ecog performance status
Item
ecog performance status of 0-1.
boolean
C1520224 (UMLS CUI [1])
recist
Item
at least one measurable lesion per recist.
boolean
C1709926 (UMLS CUI [1])
age
Item
age greater than or equal to 20 years.
boolean
C0001779 (UMLS CUI [1])
Asiens
Item
japanese, chinese, or korean ethnicity.
boolean
C0078988 (UMLS CUI [1])
cns metastases
Item
cns metastases at screening or history or cns metastases.
boolean
chemotherapeutic, cytokine-based, or other investigational agents
Item
prior targeted, chemotherapeutic, cytokine-based, or other investigational agents for the treatment of rcc within 4 weeks before first dose of test article. subjects must have documented objective progressive disease after any prior systemic rcc treatment and have recovered to grade 1 or lower toxicities from effects of prior systemic therapy for rcc.
boolean
C1514457 (UMLS CUI [1])
Malignant Neoplasms
Item
in past 5 years, other prior malignancy (except basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ).
boolean
C0006826 (UMLS CUI [1])